$2.65
2.93% yesterday
Nasdaq, Nov 25, 10:00 pm CET
ISIN
US60855D1019
Symbol
MBRX
Sector
Industry

Moleculin Biotech, Inc. Stock price

$2.65
+0.08 2.91% 1M
-2.28 46.25% 6M
-10.23 79.42% YTD
-5.62 67.94% 1Y
-30.35 91.97% 3Y
-90.95 97.17% 5Y
-717.35 99.63% 10Y
Nasdaq, Closing price Mon, Nov 25 2024
-0.08 2.93%
ISIN
US60855D1019
Symbol
MBRX
Sector
Industry

Key metrics

Market capitalization $7.96m
Enterprise Value $-940.00k
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 0.04
P/B ratio (TTM) P/B ratio 1.06
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-28.92m
Free Cash Flow (TTM) Free Cash Flow $-24.28m
Cash position $9.41m
EPS (TTM) EPS $-11.69
P/E forward negative
Short interest 4.46%
Show more

Is Moleculin Biotech, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.

Moleculin Biotech, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

2 Analysts have issued a Moleculin Biotech, Inc. forecast:

2x Buy
100%

Analyst Opinions

2 Analysts have issued a Moleculin Biotech, Inc. forecast:

Buy
100%

Financial data from Moleculin Biotech, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
- -
-
100%
- Direct Costs 0.13 0.13
43% 43%
-
-0.13 -0.13
43% 43%
-
- Selling and Administrative Expenses 8.75 8.75
15% 15%
-
- Research and Development Expense 20 20
17% 17%
-
-29 -29
5% 5%
-
- Depreciation and Amortization 0.13 0.13
43% 43%
-
EBIT (Operating Income) EBIT -29 -29
4% 4%
-
Net Profit -30 -30
15% 15%
-

In millions USD.

Don't miss a Thing! We will send you all news about Moleculin Biotech, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Moleculin Biotech, Inc. Stock News

Neutral
PRNewsWire
8 days ago
Preclinical data accepted for online publication at ASH Annual Meeting reveal significant activity of Annamycin in Venetoclax resistant AML model New preliminary clinical results show Annamycin plus Ara-C achieved 60% CR/CRi in subjects who were relapsed from or refractory to Venetoclax regimens; more than 4 times greater than published historical rates Annamycin demonstrates an even greater po...
Neutral
PRNewsWire
12 days ago
Amended protocol accelerates unblinding of preliminary primary efficacy data (CR) and safety/tolerability of the three arms at first 45 subjects Company remains on track for first subject treated in pivotal, adaptive Phase 3 clinical trial (the "MIRACLE" trial) in the first quarter of 2025 Company releases Virtual Investor "What This Means" segment discussing the amended protocol; Available her...
Neutral
PRNewsWire
14 days ago
Company on track for first subject treated in pivotal, adaptive Phase 3 clinical trial (the "MIRACLE" trial) in the first quarter of 2025 Trial designed for possible accelerated approval of Annamycin in combination with cytarabine for the treatment of relapsed or refractory AML HOUSTON , Nov. 12, 2024 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a late...
More Moleculin Biotech, Inc. News

Company Profile

Moleculin Biotech, Inc. is a clinical stage pharmaceutical company, which focuses on the development of oncology drug candidates. Its Annamycin product candidate helps in the treatment of relapsed or refractory acute myeloid leukemia. The company's preclinical small molecule portfolios focus on the modulation of hard-to-target tumor cell signaling mechanisms and the metabolism of tumors. Moleculin Biotech was founded by Walter V. Klemp, Donald H. Picker and Waldemar Priebe on July 28, 2015 and is headquartered in Houston, TX.

Head office United States
CEO Walter Klemp
Employees 18
Founded 2015
Website www.moleculin.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today